{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T11:17:27Z","timestamp":1788347847860,"version":"build-2803163510"},"reference-count":29,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:00:00Z","timestamp":1788307200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int. J. Mol. Sci.","IJMS"],"abstract":"<jats:p>Actionable ALK, ROS1, RET, NTRK, and NRG1 fusions define biologically distinct subsets of advanced non-small cell lung cancer (NSCLC), yet real-world data across these rare populations remain limited. We retrospectively evaluated patients with advanced NSCLC treated at Memorial Healthcare System who received genotype-matched fusion-directed therapy; the first fusion-directed agent defined the index treatment, and survival was measured from its initiation. Progression was determined from radiographic reports and treating-oncologist documentation. After patient-level reconciliation, 59 unique patients were included: 29 ALK, 14 ROS1, 11 RET, 3 NTRK, and 2 NRG1. Median follow-up was 47.7 months (95% CI, 28.6\u201358.7), median progression-free survival was 44.8 months (95% CI, 17.1\u2013not estimable), and median overall survival was not reached. No statistically significant survival differences were detected among ALK, ROS1, and RET subgroups, although limited sample sizes preclude exclusion of clinically meaningful differences. Later-line index therapy was not significantly associated with progression-free survival in exploratory unadjusted analysis. These findings provide descriptive real-world evidence of precision-oncology implementation across actionable fusion-defined NSCLC while underscoring that pooled outcomes should not be interpreted as evidence of equivalent efficacy across molecular subtypes or therapies.<\/jats:p>","DOI":"10.3390\/ijms27177849","type":"journal-article","created":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T10:57:23Z","timestamp":1788346643000},"page":"7849","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-World Outcomes of Fusion-Directed Targeted Therapy in Advanced Non-Small Cell Lung Cancer Harboring Actionable Gene Fusions"],"prefix":"10.3390","volume":"27","author":[{"given":"Faure","family":"Delgado Leon","sequence":"first","affiliation":[{"name":"Division of Internal Medicine, Memorial Healthcare System, 703 N Flamingo Road, Pembroke Pines, FL 33028, USA"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"conceptualization","vocabulary":"credit"},{"role":"formal-analysis","vocabulary":"credit"},{"role":"writing-original-draft","vocabulary":"credit"},{"role":"project-administration","vocabulary":"credit"},{"role":"methodology","vocabulary":"credit"},{"role":"investigation","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"},{"role":"software","vocabulary":"credit"},{"role":"data-curation","vocabulary":"credit"},{"role":"visualization","vocabulary":"credit"}]},{"given":"Suset Almuinas","family":"de Armas","sequence":"additional","affiliation":[{"name":"Division of Internal Medicine, Memorial Healthcare System, 703 N Flamingo Road, Pembroke Pines, FL 33028, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Molina","sequence":"additional","affiliation":[{"name":"Division of Internal Medicine, Memorial Healthcare System, 703 N Flamingo Road, Pembroke Pines, FL 33028, USA"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"investigation","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"},{"role":"data-curation","vocabulary":"credit"}]},{"given":"Eric G.","family":"Morales","sequence":"additional","affiliation":[{"name":"Charles E. Schmidt College of Medicine, Florida Atlantic University, Boca Raton, FL 33431, USA"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"data-curation","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9506-5282","authenticated-orcid":false,"given":"Maria","family":"Fernandez-Gomez","sequence":"additional","affiliation":[{"name":"Oncology Research Department, Memorial Cancer Institute, Memorial Healthcare System, Pembroke Pines, FL 33026, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2669-5771","authenticated-orcid":false,"given":"Luis Estuardo","family":"Raez","sequence":"additional","affiliation":[{"name":"Memorial Cancer Institute, Memorial Healthcare System, 703 N Flamingo Road, Pembroke Pines, FL 33028, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,2]]},"reference":[{"key":"ref_1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"895","DOI":"10.21037\/tlcr-22-566","article-title":"Clinical characteristics and targeted therapy of different gene fusions in non-small cell lung cancer: A narrative review","volume":"12","author":"Chen","year":"2023","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.jtho.2017.12.001","article-title":"Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology","volume":"13","author":"Lindeman","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"oyae357","DOI":"10.1093\/oncolo\/oyae357","article-title":"Emerging molecular testing paradigms in non-small cell lung cancer management\u2014Current perspectives and recommendations","volume":"30","author":"Socinski","year":"2025","journal-title":"Oncologist"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.21037\/tlcr-20-186","article-title":"Emerging oncogenic fusions other than ALK, ROS1, RET, and NTRK in NSCLC and the role of fusions as resistance mechanisms to targeted therapy","volume":"9","author":"Suda","year":"2020","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Rosas, D., Raez, L.E., Russo, A., and Rolfo, C. (2021). Neuregulin 1 gene (NRG1): A potentially new targetable alteration for the treatment of lung cancer. Cancers, 13.","DOI":"10.3390\/cancers13205038"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.annonc.2020.04.478","article-title":"Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study","volume":"31","author":"Mok","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1016\/j.annonc.2026.05.692","article-title":"Lorlatinib versus crizotinib as first-line treatment for advanced ALK-positive non-small-cell lung cancer: 7-year update from the phase III CROWN study","volume":"37","author":"Shaw","year":"2026","journal-title":"Ann. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1093\/annonc\/mdz131","article-title":"Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer: Updated results, including overall survival, from PROFILE 1001","volume":"30","author":"Shaw","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_10","first-page":"100332","article-title":"Long-term efficacy and safety of entrectinib in ROS1 fusion-positive NSCLC","volume":"3","author":"Drilon","year":"2022","journal-title":"JTO Clin. Res. Rep."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1056\/NEJMoa2302299","article-title":"Repotrectinib in ROS1 fusion-positive non-small-cell lung cancer","volume":"390","author":"Drilon","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1200\/JCO.22.00393","article-title":"Selpercatinib in patients with RET fusion-positive non-small-cell lung cancer: Updated safety and efficacy from the registrational LIBRETTO-001 phase I\/II trial","volume":"41","author":"Drilon","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1056\/NEJMoa2309457","article-title":"First-line selpercatinib or chemotherapy and pembrolizumab in RET fusion-positive NSCLC","volume":"389","author":"Zhou","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1016\/j.annonc.2022.08.002","article-title":"Safety and efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer including as first-line therapy: Update from the ARROW trial","volume":"33","author":"Griesinger","year":"2022","journal-title":"Ann. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e2100418","DOI":"10.1200\/PO.21.00418","article-title":"Efficacy and safety of larotrectinib in patients with tropomyosin receptor kinase fusion-positive lung cancers","volume":"6","author":"Drilon","year":"2022","journal-title":"JCO Precis. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1056\/NEJMoa2405008","article-title":"Efficacy of zenocutuzumab in NRG1 fusion-positive cancer","volume":"392","author":"Schram","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Hess, L.M., Han, Y., Zhu, Y.E., Bhandari, N.R., and Sireci, A. (2021). Characteristics and outcomes of patients with RET-fusion positive non-small lung cancer in real-world practice in the United States. BMC Cancer, 21.","DOI":"10.1186\/s12885-020-07714-3"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"4248","DOI":"10.1007\/s12325-024-02983-x","article-title":"Diagnosis, treatment patterns, and outcomes in real-world patients with RET fusion-positive non-small cell lung cancer in China","volume":"41","author":"Lu","year":"2024","journal-title":"Adv. Ther."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Overbeck, T.R., Reiffert, A., Schmitz, K., Rittmeyer, A., K\u00f6rber, W., Hugo, S., Schnalke, J., Lukat, L., Hugo, T., and Hinterthaner, M. (2023). NTRK gene fusions in non-small-cell lung cancer: Real-world screening data of 1068 unselected patients. Cancers, 15.","DOI":"10.3390\/cancers15112966"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1200\/JCO.20.03307","article-title":"Clinicopathologic features and response to therapy of NRG1 fusion-driven lung cancers: The eNRGy1 global multicenter registry","volume":"39","author":"Drilon","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_21","unstructured":"U.S. Census Bureau (2026, August 13). QuickFacts: Broward County, Florida. Hispanic or Latino, Percent: 35.0%, Available online: https:\/\/www.census.gov\/quickfacts\/fact\/table\/browardcountyflorida\/PST045225."},{"key":"ref_22","unstructured":"U.S. Census Bureau (2026, August 13). QuickFacts: Miami-Dade County, Florida. Hispanic or Latino, Percent: 70.6%, Available online: https:\/\/www.census.gov\/quickfacts\/fact\/table\/miamidadecountyflorida\/POP060210."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"17588359231225036","DOI":"10.1177\/17588359231225036","article-title":"Efficacy of immunotherapy in patients with oncogene-driven non-small-cell lung cancer: A systematic review and meta-analysis","volume":"16","author":"Chen","year":"2024","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e34626","DOI":"10.1016\/j.heliyon.2024.e34626","article-title":"Efficacy of immunotherapy in RET fusion-positive NSCLC: A meta-analysis","volume":"10","author":"Peng","year":"2024","journal-title":"Heliyon"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Foffano, L., Bertoli, E., Bortolot, M., Torresan, S., De Carlo, E., Stanzione, B., Del Conte, A., Puglisi, F., Spina, M., and Bearz, A. (2025). Immunotherapy in oncogene-addicted NSCLC: Evidence and therapeutic approaches. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26020583"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: Guidelines for reporting observational studies","volume":"370","author":"Altman","year":"2007","journal-title":"Lancet"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/0197-2456(96)00075-X","article-title":"A note on quantifying follow-up in studies of failure time","volume":"17","author":"Schemper","year":"1996","journal-title":"Control. Clin. Trials"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J. Am. Stat. Assoc."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression models and life-tables","volume":"34","author":"Cox","year":"1972","journal-title":"J. R. Stat. Soc. Ser. B Stat. Methodol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/17\/7849\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T10:59:34Z","timestamp":1788346774000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/17\/7849"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,2]]},"references-count":29,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["ijms27177849"],"URL":"https:\/\/doi.org\/10.3390\/ijms27177849","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,2]]}}}